entertainment -WSS

entertainment

author：comprehensive 2025-09-28 21:57:51 - browse：49761

Moderna's mResvia vaccine — The FDA has approved Moderna’s RSV vaccine for older adults. Moderna

The Food and Drug Administration on Friday approved Moderna’s vaccine to protect older adults against respiratory syncytial virus, or RSV, making this the company’s second licensed product.

The Moderna RSV vaccine, which will be marketed under the name mResvia, was approved for adults 60 and older. It is made using the same messenger RNA platform as Moderna’s other licensed product, its Covid-19 vaccine Spikevax.

“The FDA approval of our second product, mResvia, builds on the strength and versatility of our mRNA platform,” Moderna CEO Stéphane Bancel said in a statement.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： The aspartame in Diet Coke probably isn’t giving you cancer

hotspot

WSS

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

First U.S. drug developed to treat liver disease MASH is approved

FDA advisers back CAR

Swim instructor mom warns parents not to buy blue swimsuits for kids

WuXi out of biotech trade group, U.S. and China relations to blame

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Medical leaders decry Supreme Court decision on affirmative action

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Medical leaders decry Supreme Court decision on affirmative action

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

BioMarin wins approval for gene therapy to treat hemophilia A

How many hemophilia patients actually want gene therapy?

Virginia high school admissions case could be legal follow

How many hemophilia patients actually want gene therapy?

Trump demands the U.S. pay no more for drugs than other countries … again

Pushing for an NIH office for post

hotspot

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

RaDonda Vaught links Vanderbilt hospital issues to patient death

Dozens of beaches across Northeast closed for swimming due to high levels of bacteria in water

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Ebola: Gilead Sciences antiviral shows promise as new treatment

Parents surprise family after baby discharged from NICU after 170 days

focus

focus

hotspot

hotspot